Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese Populations

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 2, 2012, Pages 102-108

  Zuo, Liang Jin ^a,b   Guo, Tao ^a,b   Xia, Dong Ya ^b   Jia, Li Hui ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHENYANG NORTHERN HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DNA;

ADULT; ARTICLE; CHINA; ETHNICITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE; NORMAL HUMAN;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; YOUNG ADULT;

EID: 84857548646     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0084     Document Type: Article

References (44)

1. Alimu K, Amuti T, Niu CHY, et al. (2007) Genetic polymorphism analysis of cytochrome PYP2C19 in Chinese Uigur and Han population. J XinJiang Med Univ 30:130-132.
2. Armstrong M, Fairbrother K, Idle JR, et al. (1994) The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 4:73-81.
3. Bertilsson L, Dahl ML, Dalen P, et al. (2002) Molecular genetics of CYP2D6: clinical releVance with focus on psychotropic drugs. Br J Clin Pharmacol 53:111-122.
4. Bertilsson L, Dahl ML, Ingelman-Sundberg M, et al. (1995) Interindividual and inter-ethnic differences in polymorphic drug oxidation. Implication for drug therapy with focus on psychoactive drugs. In: Pacifici GM, Fracchia GN (eds) AdVanced in Drug Metabolism in Man. European Communities, Bruxelles, pp 86-136.
5. Bertilsson L, Lou YQ, Du YL, et al. (1992) Pronounced differences between native Chinese and Swedish population in the polymorphic hydroxylation of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 51:388-397.
6. Bertz RJ, Granneman GR (1997) Use of in vitro and in vitro data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258.
7. Cai WM, Chen B, Liu YX, et al. (1997) Dextromethorphan metabolic phenotyping in a Chinese population. Acta Pharmacol Sin 18:441-444.
8. Dai D, Tang J, Rose R, et al. (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825-831.
9. Daly AK (1995) Molecular basis of polymorphic drug metabolism. J Mol Med 73:539-553.
10. Daly AK, Cholerton S, Gregory W, et al. (1993) Metabolic polymorphism. Pharmacol Ther 57:129-160.
11. David RN, Tetsuya K, David JW, et al. (1993) The P450 superfamily: up-date on new sequence, gene mapping, accession numbers, early trivialnames of enzymes and nomenclature. DNA Cell Biol 12:1-51.
12. De Morais SMF, Wilkinson GR, Blaisdell J, et al. (1994) Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 96:594-598.
13. De Morais SMF, Wilkinson GR, Blaisdell J, et al. (1995) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269: 15419-15422.
14. Ding HW, Dong ZHW, Jiang ZG, et al. (2004) Cytochrome P450 2C19 gene polymorphism in 104 Chinese Zang volunteers. Hereditas 26:151-154.
15. Fukushima-Uesaka H, Saito Y, Watanabe H, et al. (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23:100.
16. Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58:521-590.
17. Goldstein JA, de Morais SMF (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4:285-299.
18. Goldstein JA, Ishizaki T, Chiba K, et al. (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7:59-64.
19. Hsieh KP, Lin YY, Cheng CL, et al. (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29:268-273.
20. Hu YM, Qiao M, Xu JM (2007) Study on the CYP2CI9 genetic p'hislll of Hall Chinese in Anhui province. Anhui Med Pharm J 11:717-719.
21. Ji L, Pan S, Wu J, et al. (2002) Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin Med J 115:1780-1784.
22. Kroemer HK, Eichelbaum M (1995) It's the genes, stupid. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56:2285-2298.
23. Kubota T, Yamaura Y, Ohkawa N, et al. (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50:31-34.
24. Meyer UA (1994) Pharmacogenetics the slow, the rapid, and the ultrarapid. Proc Natl Acad Sci U S A 91:1983-1984.
25. Meyer UA, Zanger UM (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37:269-296.
26. Ozdemir V, Kalow W, Tang BK, et al. (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10: 373-388.
27. Pollard SG (2004) Pharmacologic monitoring and outcomes of cyclosporine. Transplant Proc 36:404-407.
28. Qiu XY, Jiao Z, Zhang M, et al. (2008) Association of MDR1, CYP3A4.*18B and CYP3A5.*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 64:1069-1084.
29. Rioux PP (2000) Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am J Health Syst Pharm 57:887-901.
30. Ruzilawati AB, Gan SH (2010) CYP3A4 Genetic polymorphism influences repaglinide's pharmacokinetics. Pharmacology 85: 357-364.
31. Sachse C, Brockmoller J, Bauer S, et al. (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295.
32. Shimizu T, Ochiai H, Asell F, et al. (2003) Bioinformatics research on inter-racial difference in drug metabolism. I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 18:48-70
33. Shulman RW, Ozdemir V (1997) Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly. Can J Psychiatry 42:4-9.
34. Thummel KE, Wilkinson GR (1998) In vitro and in vivo interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430.
35. Wang AN, Zhou HH (2005) AdVance in search for cytochrome P450 3A4 gene mutation and phenotype. Chin J Clin Pharmacol 6:459-461.
36. Wolf CR, Smith G (1999) Cytochrome P450 CYP2D6. IARC Sci Publ 148:209-229.
37. Wrighton SA, VardonBradon M, Ring BJ (1996) The human drug metabolizing cytochromes P450. J Pharm Biopharm 24: 461-473.
38. Yin OQP, Shi XJ, Tomlinson B, et al. (2005) Effect of CYP2D6. *10 allele on the pharmacokinetics of loratadine in Chinese subjects. Drug Metab Dispos 33:1283-1287.
39. Yogita G, Kalpana J, Yashendra A, et al. (2007) Genetic polymorphism of CYP2C19 in Maharashtrian population. Eur J Epidemiol 22:907-915.
40. Zanger UM, Turpeinen M, Klein K, et al. (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093-1108.
41. Zeng Y, He YJ, He FY, et al. (2009) Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4. * 18B genotype in healthy subjects. Acta Pharmacol Sin 30:478-484.
42. Zhan GS, Zhou Q, Dong ZHW (2001) Cytochrome P450 2C19 gene polymorphism in Chinese Miao population. Hereditas 23:192-194.
43. Zhang S, Dong ZHW, Tang L, et al. (2002) Cytochrome P450 2C19 gene polymorphism in four Chinese nationality population. Chin J Med Genetl 9:52-54.
44. Zhen Y, Wu YJ, Wu YM (2007) Single nucleotide polymorphism of CYP2D6 C188T and susceptibillty to lung cancer. J Environ Occup Med 2:167-169.